

Supplementary Figure 1. Flow chart demonstrating the inclusion-exclusion of studies in the meta-analysis.

Study Age group	Variant	Genotyping method	Risk of bias
Di Sessa, 2018; Paediatric	rs641738 C>T	Taqman assay	5
Sookoian, 2018; Adult	rs641738 C>T	Taqman assay	5
Di Costanzo, 2018; Adult	rs641738 C>T	Taqman assay	3 (a,c)
Lin, 2018; Paediatric	rs641738 C>T	Taqman assay	5
Viitasalo, 2016; Paediatric	rs641738 C>T	Taqman assay	3 (c,d)
Koo, 2018; Adult	rs641738 C>T	Taqman assay	5
Hudert, 2018; Paediatric	rs641738 C>T	Taqman assay	3 (a,c)
Mann, 2018a; Adult	rs641738 C>T	Affymetrix 500K Array Set, Affymetrix Axiom UKBiobank, and Illumina Infinium Core Exome 24v1	5
Mann, 2018b; Paediatric	rs641738 C>T	Taqman assay	5
Umano, 2018; Paediatric	rs626283 G>C	Taqman assay	4 (c)
Krawczyk, 2018; Adult	rs641738 C>T	Taqman assay	4 (c)
Krawczyk, 2017; Adult	rs641738 C>T	Taqman assay	5
Kawaguchi, 2018; Adult	rs641738 C>T	Illumina Human 610-Quad, Illumina Human Omni 2.5-8, and Illumina Infinium Core Exome arrays	4 (a)
Dongiovanni, 2018; Adult	rs641738 C>T	Taqman assay	5
Dongiovanni, 2018b;	rs641738 C>T	Taqman assay	5

Adult			
Mancina, 2016; Adult	rs641738 C>T	Taqman assay	5
Luukkonen, 2016; Adult	rs641738 C>T	Taqman assay	5
Donati, 2017; Adult	rs641738 C>T	Taqman assay	5
DiStefano, 2015; Adult	rs641738 C>T	Infinium HD Ultra BeadChip assay	5
Adams, 2013; Paediatric	rs641738 C>T	lluminaHuman660-W Quad Array	5
Lauridsen, 2018; Adult	rs641738 C>T	Taqman assay	5
Speliotes 2011; Adult	rs641738 C>T	Illumina, Affymetrix 500K & Affymetrix 50K, and iPLEX Sequenom MassARRAY arrays	5
Strnad, 2018; Adult	rs641738 C>T	Taqman assay	4 (a)
Emdin, 2019; Adult	rs641738 C>T	UK Biobank Axiom Array	4 (d)
Reichert, 2019; Adult	rs641738 C>T	Taqman assay	4 (c)
Guzman, 2018; Adult	rs2576452 C>T	Affymetrix Axiom array	4 (a)
Luukkonen, 2018; Adult	rs641738 C>T	Taqman assay	5
Wattacheril, 2017; Paediatric	rs641738 C>T	Illumina HumanCNV370-Quadv3 BeadChips	5
Chatterjee, 2018; Adult	rs641738 C>T	Illumina Illumina-Human Exome Bead chip version 1.2	5
UKBB, 2019; Adult	rs641738 C>T	UK Biobank Axiom Array	5
Abeysekera, 2019;	rs641738 C>T	Illumina SNP arrays: 317, 610, and 550 (custom)	5

Adult			

Supplementary table 1. Additional characteristics of included studies. A modified Cochrane Risk-of-Bias Tool (0-5) was used. Letters indicate risk of bias due to a corresponding component of the score:
A: Similarity of cases and controls
B: Quality of genotyping
C: Assessment of potential confounders
D: Method of assessing outcome
E: Adequate follow-up



Supplementary Figure 2. The effect of rs641738C>T on liver fat in Caucasian individuals (or of European ethnicity). Data from 19,329 individuals with CT or MR liver fat. T-allele was associated with a small increase in liver fat, where data represents standard deviation change in normalized liver fat per T-allele. CGPS, Copenhagen General Population Study; CI, confidence interval; ES, effect summary; GOLD, Genetics of Liver Disease; N, number of individuals included; UKBB, UK BioBank.



Supplementary Figure 3. Sensitivity analysis for the presence of NAFLD using the leave-one-out method based on an additive model of inheritance and using random effects. ALSPAC, Avon Longitudinal Study of Parents and Children.



Supplementary Figure 4. Funnel plot for the presence of NAFLD based on an additive model of inheritance and using random effects. Egger's test p=.23.



Supplementary Figure 5. rs641738C>T is associated with histological severity of steatosis in Caucasian individuals, using an additive model of inheritance. Data from 19,648 adults with radiologically defined steatosis for presence versus absence of NAFLD (A) and 4,073 adults with liver biopsy data for presence of severe steatosis (S0-2 versus S3, B). ALSPAC, Avon Longitudinal Study of Parents and Children.



Supplementary Figure 6. The effect of rs641738C>T on liver fat using ultrasound and controlled attenuation parameter (CAP). Data from 12,197 individuals with liver fat semi-quantitatively scored using ultrasound or with CAP. Data represents standard deviation change in normalized liver fat per T-allele. ALSPAC, Avon Longitudinal Study of Parents and Children.



Supplementary Figure 7. rs641738C>T is associated with higher odds of NASH on biopsy in Caucasian individuals. Data from 4,433 adults with NASH defined according to the FLIP algorithm. NAFL, non-alcoholic fatty liver.



Supplementary Figure 8. Sensitivity analysis for the presence of advanced fibrosis or cirrhosis using the leave-one-out method based on an additive model of inheritance and using random effects.



Supplementary Figure 9. rs641738C>T is associated with advanced fibrosis in Caucasian individuals with NAFLD. A, data from 6,787 adults with biopsy-proven NAFLD (plus coding data from Emdin et al.) comparing advanced fibrosis (F3-4) versus F0-2, using an additive model of inheritance. B, data from 5,425 adults with biopsy-proven NAFLD comparing any fibrosis (F1-4) versus no fibrosis F0.

Trait	Beta	p-value	Cases (n)	Total (n)	Study reference
Top phenotypic associations (ranked by p-value)					
Platelet count	0.84	2.3E-20		452264	UKBB (from Canela-Xandri 2018)
Red blood cell (erythrocyte) count	-0.003	2.1E-07		452264	UKBB (from Canela-Xandri 2018)
Haemoglobin concentration	-0.009	2.8E-07		452264	UKBB (from Canela-Xandri 2018)
Neutrophill count	-0.01	1.6E-06		452264	UKBB (from Canela-Xandri 2018)
Monocyte percentage	0.02	2.5E-06		452264	UKBB (from Canela-Xandri 2018)
Alkaline phosphatase	0.005	6.1E-06		61089	Chambers 2011
Haematocrit percentage	-0.02	2.5E-05		452264	UKBB (from Canela-Xandri 2018)
Eosinophill percentage	0.01	3.2E-05		452264	UKBB (from Canela-Xandri 2018)
White blood cell (leukocyte) count	-0.01	3.4E-05		452264	UKBB (from Canela-Xandri 2018)
Fracture of skull and facial bones	0.0005	1.6E-04	913	337199	UKBB (from Neale 2017)
Lymphocyte percentage of white cells	0.01	5.3E-04		173480	Astle 2016
Estimated bone mineral density	0.007	5.9E-04		426824	Morris 2019
Self-reported peritonitis	-0.0005	8.6E-04	1158	337159	UKBB (from Neale 2017)
Mean corpuscular hemoglobin concentration	-0.01	1.1E-03		173480	Astle 2016
High density lipoprotein cholesterol	0.018	1.2E-03		188577	GLGC 2013
Trunk fat percentage	0.04	1.4E-03		452264	UKBB (from Canela-Xandri 2018)
Excessive, frequent and irregular menstruation	0.001	1.4E-03	6882	337199	UKBB (from Neale 2017)
M67 Other disorders of synovium and tendon	0.0006	2.1E-03	4141	452264	UKBB (from Canela-Xandri 2018)
Birth weight	0.01	2.3E-03		193063	UKBB (from Neale 2017)
Urethral stricture	0.0005	2.4E-03	1343	337199	UKBB (from Neale 2017)
Body fat percentage	0.03	2.5E-03		452264	UKBB (from Canela-Xandri 2018)
Complications of other internal prosthetic devices, implants and grafts	-0.0004	3.7E-03	889	337199	UKBB (from Neale 2017)
Illnesses of mother: alzheimers disease or dementia	-0.002	4.0E-03	26757	309843	UKBB (from Neale 2017)
Self-reported heart arrhythmia	0.0005	4.1E-03	1862	337159	UKBB (from Neale 2017)
Stroke	0.0007	4.3E-03	6465	452264	UKBB (from Canela-Xandri 2018)
Number of self-reported cancers	-0.002	5.2E-03		452264	UKBB (from Canela-Xandri 2018)
Trunk fat mass	0.02	5.3E-03		452264	UKBB (from Canela-Xandri 2018)
Ventral hernia	-0.0005	6.5E-03	1536	337199	UKBB (from Neale 2017)

Self-reported stomach disorder	0.0003	6.5E-03	718	337159	UKBB (from Neale 2017)
Illnesses of mother: high blood pressure	-0.003	6.9E-03	94817	311681	UKBB (from Neale 2017)
Kidney stone/ureter stone/bladder stone	-0.0005	7.2E-03	3522	452264	UKBB (from Canela-Xandri 2018)
Self-reported kidney or renal cell cancer	-0.0002	7.9E-03	436	337159	UKBB (from Neale 2017)
K76 Other diseases of liver	0.0005	8.7E-03	3737	452264	UKBB (from Canela-Xandri 2018)
Right eye cataract	-0.02	8.7E-03	815	3882	UKBB (from Neale 2017)
Gout	-0.0006	9.5E-03	6389	452264	UKBB (from Canela-Xandri 2018)
Cardio-metabolic and liver-related traits with p>0.01					
K70-K77 Diseases of liver	0.0006	0.01	5472	452264	UKBB (from Canela-Xandri 2018)
Whole body fat mass	0.04	0.01		452264	UKBB (from Canela-Xandri 2018)
M81 Osteoporosis without pathological fracture	0.0006	0.02	6601	452264	UKBB (from Canela-Xandri 2018)
Cause of death: intracerebral haemorrhage, unspecified	0.003	0.02	57	7637	UKBB (from Neale 2017)
Angina	-0.0008	0.02	14399	452264	UKBB (from Canela-Xandri 2018)
Leptin	-0.01	0.03		32161	Kilpeläinen 2016
Triglycerides	-0.03	0.03		9961	Prins 2017
Vascular or heart problems diagnosed by doctor: stroke	0.0006	0.03	5198	336683	UKBB (from Neale 2017)
Hip circumference	0.03	0.04		452264	UKBB (from Canela-Xandri 2018)
K74 Fibrosis and cirrhosis of liver	0.0002	0.04	901	452264	UKBB (from Canela-Xandri 2018)
K70 Alcoholic liver disease	0.0002	0.07	919	452264	UKBB (from Canela-Xandri 2018)
Type 2 diabetes	OR: 1.01	0.09		898130	Mahajan 2018
K75 Other inflammatory liver diseases	-0.0001	0.11	734	452264	UKBB (from Canela-Xandri 2018)
Bilirubin	-0.03	0.12		7159	Mahajan 2018
Intermediate density lipoprotein cholesterol	0.02	0.17		19291	Locke 2019
Alanine transaminase	0.003	0.18		61089	Chambers 2011
Triglycerides	-0.004	0.18		177861	GLGC 2013
Gamma-glutamyl transferase	-0.004	0.24		61089	Chambers 2011
Bone fracture	OR: 0.99	0.24		426824	Morris 2019
Total cholesterol	0.006	0.26		187365	GLGC 2013
Diastolic blood pressure	-0.002	0.39		317756	UKBB (from Neale 2017)
Systolic blood pressure	-0.001	0.59		317754	UKBB (from Neale 2017)
Fasting glucose	0.003	0.59		46186	Dupuis 2010

Low density lipoprotein	0.0009	0.61		173082	GLGC 2013
Body mass index	0.001	0.62		526508	Turcot 2018
Aspartate aminotransferase	0.0008	0.74		61089	Chambers 2011
Coronary artery disease	-0.0012	0.84	122733	547261	van der Harst 2018
HbA1c	-0.0003	0.87		123665	Wheeler 2017
Waist circumference	-0.0004	0.93		244441	Shungin 2015

Supplementary table 2. Phenotypes associated with rs641738C>T identified through Phenoscanner and GeneATLAS. All traits with p<0.01 are listed and then all cardiometabolic traits of potential relevance to NAFLD are listed beneath. GLGC, Global Lipids Genetics Consortium.

Additive model of inheritance	Number of cohorts	P_Q	I^2	Random effects		
				OR	[95% CI]	P_z
Presence of NAFLD Controls (n=2,431) vs. NAFLD (n=608)	4	.93	0	.99	.87, 1.13	.89
Severe steatosis S0-2 (n=193) vs. S3 (n=152)	3	.45	0	1.21	.89, 1.64	.24
Presence of NASH NAFL (n=102) vs. NASH (n=243)	3	.91	0	1.01	.72, 1.43	.95
Any fibrosis F0 (n=224) vs. F1-4 (n=117)	3	.99	0	.55	.71, 1.39	.97

Supplementary table 3. Meta-analysis for the effect of rs641738C>T on radiological diagnosis of NAFLD and presence of histological features of NAFLD in children, using an additive genetic model and random effects.



Supplementary Figure 10. rs641738C>T is not significantly associated with hepatic fat fraction (A), presence of NAFLD (B), or histological severe steatosis (C) in children. A, data from 910 children with MRI liver fat, where effect summary represents standard deviation change in normalized liver fat per T-allele. B, 3,039 children with radiologically defined steatosis for presence versus absence of NAFLD, and C, 345 with liver biopsy data (S0-2 versus S3).